- Positive survival data from KEYNOTE-905 and KEYNOTE-B96 will be featured in the Presidential Symposium.
- Merck will present data from over 100 abstracts across more than 20 cancer types at ESMO 2025.
- New results from REJOICE-Ovarian01 evaluate raludotatug deruxtecan for platinum-resistant ovarian cancer.
- Long-term data supports KEYTRUDA's role in treating non-small cell lung cancer.
Key Data Presentations
Merck will present positive survival data from the KEYNOTE-905 and KEYNOTE-B96 studies at the Presidential Symposium during the ESMO 2025 Congress. These studies highlight the impact of KEYTRUDA (pembrolizumab) in treating certain bladder and ovarian cancers.
Innovative Pipeline
Data from Merck's innovative pipeline will be showcased, including new findings from the REJOICE-Ovarian01 study. This study evaluates raludotatug deruxtecan (R-DXd) for patients with platinum-resistant ovarian cancer.
Long-term Efficacy
Long-term data for KEYTRUDA in both earlier and metastatic non-small cell lung cancer will be presented, supporting its foundational role in treating this cancer type.
Comprehensive Research
Merck will present research from over 100 abstracts covering more than 20 types of cancer and various treatment settings. This demonstrates Merck's commitment to advancing research across multiple tumor types to improve patient outcomes.
